Alternative Anxiolytics Comparison
Alternative Anxiolytics Comparison
Quick Reference Tool | PsychHQ Source: Module 3, Pharmacotherapy (Lessons 4, 5, 6, 7) | Last Updated: March 2026
When You're Looking Beyond SSRIs and Benzodiazepines
These agents occupy specific niches in anxiety treatment. None replace SSRIs as first-line, but each solves a particular clinical problem that SSRIs don't. The evidence quality varies widely — from strong RCT data (pregabalin) to expert consensus with minimal controlled trials (trazodone for anxious insomnia). This tool gives you the positioning and evidence base for each.
Head-to-Head Comparison
| Feature | Buspirone | Hydroxyzine | Pregabalin | Gabapentin | Propranolol | Mirtazapine | Trazodone |
|---|---|---|---|---|---|---|---|
| Class | 5-HT1A partial agonist (acts on a serotonin receptor subtype) | H1 antihistamine (blocks histamine receptors) | Alpha-2-delta ligand (reduces calcium-dependent neurotransmitter release) | Alpha-2-delta ligand (same class as pregabalin) | Non-selective beta-blocker (blocks adrenaline's physical effects) | NaSSA (boosts norepinephrine + directs serotonin to anxiolytic pathways) | SARI (blocks certain serotonin receptors + mild reuptake inhibition) |
| Effect size | 0.17 (small) | 0.45 (moderate) | 0.50 (moderate-large) | 0.78 for SAD only; weak elsewhere | Strong for performance anxiety only | Weak anxiety-specific data | Historical: 69% vs 47% placebo (Rickels 1993 GAD trial) |
| NNT | High (weak monotherapy) | Moderate | 5-8 | High | N/A | N/A | Moderate |
| Onset | 2-4 weeks | 30-60 min | ~Day 4 | Variable | 60-90 min (PRN) | 1-2 weeks (sedation immediate) | 30-60 min (sleep effect) |
| FDA anxiety indication | Yes (GAD) | Yes (anxiety) | No (US); Yes (EU/UK/Canada for GAD) | No | No | No | No |
| Controlled substance | No | No | Schedule V (US); Schedule 3 (UK) | No | No | No | No |
| Dependence risk | None | None | Yes (rebound anxiety, insomnia, rarely seizures on abrupt D/C) | Minimal | None | None | None |
Agent-by-Agent Clinical Guide
Buspirone
Reach for this when: Patient has SUD history (benzodiazepines contraindicated), elderly patient where benzodiazepine risks outweigh benefits, or as augmentation in anxious depression.
The realistic assessment: Effect size of 0.17 is the lowest of any anxiolytic — smaller than every other agent in this tool. It works — but modestly, and only after 2-4 weeks of consistent dosing. The 2-4 week onset lag is the single biggest adherence barrier: patients expecting benzodiazepine-like relief will stop taking it before it has a chance to work. Set expectations upfront.
Dosing: 7.5 mg BID → titrate by 5 mg every 2-3 days; therapeutic range 20-45 mg/day; max 60 mg/day. Short half-life (2-3 hrs) requires divided dosing (BID-TID). Food alters bioavailability — counsel to take consistently with or without food.
Post-benzodiazepine patients: Frequently report "it doesn't work." This isn't imagination — prior benzodiazepine exposure creates neuroadaptive changes that genuinely reduce buspirone's subjective effect. Don't dismiss the patient's experience; consider alternative agents.
As augmentation: Recent data shows buspirone augmentation in anxious depression decreased HAM-A from 25.2 to 15.4 (p<0.001) with only 3.7% adverse events. Note that monotherapy evidence is actually stronger than augmentation evidence (SSRI nonresponder RCTs failed to separate from placebo due to high placebo response). Real-world augmentation dosing is often suboptimal — 10-15 mg is too low; push to 30-60 mg/day divided.
Hydroxyzine
Reach for this when: Young adults needing PRN anxiolysis without dependence risk; short-term use while SSRI titrates in patients who refuse benzodiazepines.
Two formulations:
- HCl (Atarax): better for acute/PRN use
- Pamoate (Vistaril): marketed for chronic anxiety
Evidence: Head-to-head with bromazepam (a benzodiazepine): non-inferior anxiolysis with lower rebound anxiety upon discontinuation.
The age problem: Safe as PRN in young adults (25-50 mg as needed), but the risk-benefit inverts in the elderly. Beers Criteria (2023) lists hydroxyzine for avoidance in adults over 65 due to anticholinergic burden (confusion, urinary retention, constipation, dry mouth). QTc prolongation risk exists even at therapeutic doses.
Dosing: PRN: 25-50 mg as needed, max 100 mg/day. Scheduled: 50-100 mg/day in divided doses. Rapid tolerance to sedation develops within days, which limits chronic utility — the patient adapts to the sleepiness but may retain some anxiolytic benefit.
Pregabalin
Reach for this when: GAD with prominent somatic symptoms, faster onset needed than SSRIs can provide, facilitating benzodiazepine taper, or elderly patients (dedicated geriatric trial data exists).
The strongest non-antidepressant anxiolytic. Effect size of 0.50 (exceeds SSRIs) with NNT 5-8 and remarkably fast onset — clinically apparent by day 4. Mechanism: selectively reduces calcium flow into overactive nerve endings, which decreases release of excitatory neurotransmitters (glutamate, norepinephrine, substance P). Despite the name similarity to GABA (the brain's main inhibitory neurotransmitter), pregabalin does NOT bind GABA-A or GABA-B receptors.
The US regulatory situation: FDA rejected pregabalin for GAD in 2004 and 2009 — not because of efficacy failure but because too many individual trials failed despite strong meta-analytic evidence. Approved in the EU, UK, and Canada for GAD. US prescribing is off-label.
Abuse liability — take seriously: Pregabalin is Schedule V in the US, Schedule 3 in the UK. In poisoning data, 88% of pregabalin poisoning cases involve co-ingestion (opioids 41%, benzodiazepines 36%). Abuse potential is higher than many clinicians assume and may exceed benzodiazepines in some populations.
Physical dependence: Possible with chronic use. Abrupt discontinuation can cause rebound anxiety, insomnia, nausea, and rarely seizures. Taper gradually.
Dosing: Start 75 mg BID (150 mg/day) → increase to 150 mg BID (300 mg/day) after 1 week; max 600 mg/day, though most benefit occurs at 150-300 mg/day. Side effects: dizziness, somnolence, dose-dependent weight gain.
Gabapentin
Reach for this when: Not often — pregabalin is the better-supported alpha-2-delta ligand for anxiety.
The problem is pharmacokinetics. Gabapentin shares pregabalin's mechanism but uses a saturable intestinal transporter (LAT1) that makes absorption non-linear and unpredictable. Bioavailability drops as doses increase, so escalation beyond ~1,800 mg/day shows diminishing returns regardless of how high you push.
Evidence is narrow: Moderate effect size (0.78) exists for social anxiety disorder only. GAD and panic disorder evidence is essentially absent. Widespread off-label anxiety use is driven by low cost and lack of scheduling, not by data.
If you're going to use it: 300-600 mg TID (900-1,800 mg/day). Escalate slowly. If it doesn't work at 1,800 mg/day, more gabapentin won't help — consider pregabalin or a different class.
Propranolol
Reach for this when: Performance anxiety only — the musician about to go on stage, the executive about to give a presentation, the student before a board exam.
What it does: Blocks peripheral autonomic symptoms of anxiety (tachycardia, tremor, sweating, voice tremor) by non-selective beta-1/beta-2 antagonism. Does NOT alter central worry, rumination, or cognitive anxiety symptoms. The patient still feels anxious mentally but their body doesn't betray them.
What it doesn't do: There is no evidence supporting propranolol for GAD, panic disorder, or any chronic anxiety condition as daily monotherapy. Do not prescribe it this way.
Safety concern: Narrow margin between therapeutic and lethal doses in overdose. Severe bradycardia, hypotension, and cardiogenic shock. UK coroner reports specifically warn about deaths in young anxious patients prescribed propranolol for chronic daily use. Reserve for PRN performance anxiety only.
Dosing: 10-40 mg taken 60-90 min before performance event. Contraindicated in asthma (beta-2 blockade → bronchospasm), bradycardia, or heart block.
Mirtazapine
Reach for this when: Anxious depression with severe insomnia and/or appetite loss (both sedation and weight gain become therapeutic features rather than side effects); elderly anxious-depressive patients with sleep disruption; augmenting an SSRI that's causing insomnia.
The dose-sedation paradox: 7.5-15 mg is heavily sedating (histamine H1 blockade dominates at low doses). At 30-45 mg, noradrenergic and serotonergic effects offset the H1 sedation — so higher doses are actually less sedating. This counterintuitive pharmacology confuses patients and some clinicians.
Mechanism: Blocks alpha-2 autoreceptors (removes the norepinephrine "brake") plus 5-HT2A/2C/3 antagonism (directing serotonin toward the anxiolytic 5-HT1A pathway). No sexual dysfunction — a meaningful advantage over SSRIs.
Limited anxiety-specific evidence: Not first- or second-line for anxiety by any guideline. A recent open-label trial showed 79.5% response and 36.4% remission in anxious depression at 30 mg/day, but open-label limitations apply.
Dosing: Start 15 mg at bedtime (expect sedation) → titrate to 30 mg after 1-2 weeks; max 45 mg/day. The "California Rocket Fuel" combination (mirtazapine + venlafaxine) is pharmacologically rational for treatment-resistant anxiety-depression but watch for additive sedation.
Trazodone
Reach for this when: Anxiety-driven insomnia where you want a non-habit-forming hypnotic that improves sleep architecture (increases slow-wave sleep without suppressing REM).
Two drugs in one molecule depending on dose:
- Low doses (25-100 mg): primarily 5-HT2A, H1, and alpha-1 antagonism — full receptor saturation at these doses. NOT functioning as an SSRI at this range. This is the sleep/anxiolysis dose.
- High doses (150-300 mg): meaningful SERT inhibition (~86% at 150 mg) — now acting as a true antidepressant. Rarely prescribed at this range for anxiety.
Historical anxiety data: Rickels et al. (1993), 230 GAD patients, 8 weeks: comparable anxiolysis to diazepam from weeks 3-8; 69% moderate-to-marked improvement vs 47% placebo; actually superior to diazepam for psychic anxiety (tension, worry). This study is rarely cited today, but the data exist.
Critical adverse effects — counsel every patient:
- Priapism (prolonged painful erection): rare but a urological emergency. Caused by alpha-1 blockade in cavernosal tissue. All male patients must be warned.
- Orthostatic hypotension: 43.8% prevalence in elderly hypertensives; fall rate 58.3% vs 21.2% in non-users. Alpha-1 blockade. Stand up slowly; measure orthostatic vitals.
- QTc prolongation: documented risk. Obtain baseline ECG in patients with arrhythmia history.
Dosing (low-dose anxiolytic/hypnotic): 25-50 mg at bedtime → titrate to 50-100 mg as needed. Minimal next-day sedation (half-life 3-6 hrs).
Quick Decision Matrix
| Clinical Scenario | First Choice | Alternative |
|---|---|---|
| SUD history, need non-BZ anxiolytic | Buspirone | Hydroxyzine (PRN, young adults) |
| Fast onset needed while SSRI titrates | Pregabalin (if available/appropriate) | Hydroxyzine PRN |
| Performance anxiety only | Propranolol PRN | — |
| Anxiety-driven insomnia | Trazodone (low-dose) | Mirtazapine (if depression co-occurs) |
| Anxious depression + insomnia + weight loss | Mirtazapine | Trazodone + SSRI |
| GAD with prominent somatic symptoms | Pregabalin | Buspirone augmentation |
| Facilitating benzodiazepine taper | Pregabalin | Gabapentin |
| Elderly patient needing anxiolysis | Buspirone | Pregabalin (geriatric trial data) |
| Social anxiety (SSRI-resistant) | Pregabalin or gabapentin | Phenelzine (see TCA & MAOI Prescribing Guide — effect size 1.02, largest of any anxiety medication) |
Key References: Fernandes et al. (2025, NMA, GAD); Linares et al. (2019, CBD dose-response); Rickels et al. (1993, trazodone vs. diazepam); Pratte et al. (2014, ashwagandha meta-analysis); Boyle et al. (2017, magnesium review); Gray et al. (2015, anticholinergic-dementia risk); Strawn et al. (2017, guanfacine pilot RCT)